A5055712072- Renal Diseases and Glomerulopathies
- Vasculitis and related conditions
- Renal Transplantation Outcomes and Treatments
- Complement system in diseases
- Chronic Kidney Disease and Diabetes
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Systemic Lupus Erythematosus Research
- Dialysis and Renal Disease Management
- COVID-19 Clinical Research Studies
- Acute Kidney Injury Research
- Neurological Complications and Syndromes
- Pregnancy and Medication Impact
- Autoimmune Bullous Skin Diseases
- Renal and Vascular Pathologies
- Biomedical Research and Pathophysiology
- Parathyroid Disorders and Treatments
- Abdominal vascular conditions and treatments
- Pharmacological Effects and Toxicity Studies
- Polyomavirus and related diseases
- Systemic Sclerosis and Related Diseases
- COVID-19 and healthcare impacts
- Genetic Syndromes and Imprinting
- Inflammatory Myopathies and Dermatomyositis
- Platelet Disorders and Treatments
- Adenosine and Purinergic Signaling
Boston Medical Center
2023-2025
Boston University
2023-2025
Northwell Health
2022-2024
Feinstein Institute for Medical Research
2023
Post Graduate Institute of Medical Education and Research
2017-2023
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
2022-2023
Hofstra University
2023
North Shore University Hospital
2022
All India Institute of Medical Sciences
2016-2019
The number of deaths attributable to CKD in India rose from 0.59 million 1990 1.18 2016 (1). Data on incidence and prevalence kidney failure remain estimates because there are no registries. Million Death Study estimated the be 136,000 2015 (2). A 2018 estimate put patients chronic dialysis at about 175,000, giving a 129 per population (3). systematic review that two thirds all with died without receiving 2010 (4). The burden is greater comparison other low- middle-income economies similar...
Chronic kidney disease (CKD) is a unique public health problem in terms of high expenses required for its management and increasing worldwide incidence. Understanding the existing structure CKD treatment epidemiology pivotal equitable care globally. The Global Kidney Health Atlas (GKHA) was launched by International Society Nephrology (ISN) 2017 as part "Bridging Gaps" strategy with vision to understand global capacity. Two rounds GKHA surveys were conducted published 2019, respectively....
The coexistence of two different malignancies in one site is rare. Development renal cell carcinoma (RCC) and lymphoma the same individual speculated to be due common immune mechanism and/or genetic predisposition. We report a tumor comprising RCC localized primary diffuse large B-cell (DLBCL) native kidney 53-year-old transplant recipient after 15 years transplant. Patient had stable function on tacrolimus, mycophenolate mofetil (MMF) prednisolone. On trauma pan scan (as he reported an...
e16543 Background: Vascular endothelial growth factor inhibitors (VEGFi) are commonly used in cancer therapy. VEGFi can cause hypertension by interference with nitric oxide-mediated vasodilation. The incidence of from varies due to different definitions clinical trials. Understanding the timeline and predictors onset could improve patient management. Methods: This single-center prospective cohort study includes patients without diabetes, hypertension, or proteinuria scheduled for systemic...
ABSTRACT Aim A significant proportion of patients with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are either steroid dependent or resistant, requiring long‐term calcineurin inhibitors (CNI) use. Rituximab has more favourable safety profile. The present study was undertaken to evaluate the efficacy rituximab in CNI‐dependent patients. Methods This a prospective observational conducted from July 2014 February 2018. Steroid‐dependent nephrotic syndrome...
CKD is a growing public health problem. The Global Kidney Health Atlas (GKHA) an important initiative of the International Society Nephrology. GKHA aims to improve understanding inter- and intranational variability across globe, focusing on capacity for kidney care delivery. survey was launched in 2017 then again 2019, using same core data, supplemented by information about dialysis access conservative care. Based WHO framework 6 building blocks essential care, assesses domains: systems,...
Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommends cyclical cyclophosphamide plus glucocorticoids (GC) (modified Ponticelli regimen) or calcineurin inhibitors (CNIs) such as tacrolimus (TAC) cyclosporine the first-line agents for management of primary membranous nephropathy (PMN) that is resistant to antiproteinuric therapy with renin-angiotensin system blockers. However, long-term outcome patients treated CNIs not known.We report outcomes 70 randomized 1:1 receive modified...
Abstract Dialysis adequacy is conventionally quantified as net urea clearance. Single pool (sp) Kt/V remains the best studied measure of dialysis globally. Other measures such fluid status control, anemia correction, and mineral metabolism are monitored variably. Increasing use hemodiafiltration across Europe many parts Japan Australia predicated on studies showing better patient survival with middle molecule Apart from local clinical practice guidelines, income level public health policy a...
MicroRNAs (miRNAs) are noncoding small RNAs that regulate the protein expression of coding messenger RNAs. They used as biomarkers to aid in diagnosing, prognosticating, and surveillance diseases, especially solid cancers. MiR-193a was shown be directly pathogenic an experimental mouse model focal segmental glomerulosclerosis (FSGS) during last decade. Its specific binding downregulation Wilm’s tumor-1 (WT-1), a transcription factor regulating podocyte phenotype, is documented. Also,...
Abstract Rituximab is currently used after the conventional agents have failed in management of steroid‐dependent (SD)/ steroid‐resistant (SR) podocytopathies and a safer toxicity profile. We report 53 adults with who were managed effectively CD19‐targeted rituximab therapy. Methods This was prospective study carried out at tertiary care centre India between January 2014 June 2019. Adults 16 60 years SD, frequently relapsing (FR), SR nephrotic syndrome (NS) due to podocytopathy received...
The Kidney Disease Improving Global Outcomes guidelines recommend incorporating anti-M-type Phospholipase A2 receptor (PLA2R) antibody titers in steering treatment decisions for patients with primary membranous nephropathy (PMN).1